Meanwhile, a new subcutaneous formulation of Takeda’s Entyvio (vedolizumab) – currently given as an intravenous infusion – was recommended for approval by the EMA as a maintenance therapy in ...
It will compete with other biologic therapies for Crohn's, including J&J's IL-12 and IL-23 inhibitor Stelara (ustekinumab), Takeda's Entyvio ... followed by a 360mg subcutaneous shot given ...
After hours: February 7 at 6:26:17 p.m. EST ...
After hours: 7 February at 18:26:17 GMT-5 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback